首页> 外国专利> Recombinant fusion protein produced by fusing Vibrio vulnificus flagellin and pathogenic antigens and the mucosal vaccine containing the same as an active ingredient

Recombinant fusion protein produced by fusing Vibrio vulnificus flagellin and pathogenic antigens and the mucosal vaccine containing the same as an active ingredient

机译:通过融合创伤弧菌鞭毛蛋白和致病性抗原产生的重组融合蛋白以及含有该融合蛋白作为有效成分的粘膜疫苗

摘要

PURPOSE: A recombinant fusion protein prepared by fusing antigen of pathogen with vaccine adjuvant and a vaccine for mucosal administration is provided to enhance PspA-specific antibody(IgG and IgA) generation. CONSTITUTION: A recombinant fusion protein is prepared by fusing protein antigen of pathogen with flagellin protein of Vibrio vulnificus. The flagellin is a FlaB of Vibrio vulnificus of sequence number 1. The antigen of pathogen is an alpha-helix domain and surface adhesion factor A(PsaA) of Streptococcus pneumoniae surface protein A(PsaA); subunit HA(hemagglutinin) and NA(neuraminidase) of influenza virus; or spike(S) protein of SARS virus. A vaccine for mucosal administration contains the recombinant fusion protein as an active ingredient.
机译:目的:提供一种融合病原体抗原与疫苗佐剂和粘膜给药疫苗的重组融合蛋白,以增强PspA特异性抗体(IgG和IgA)的产生。组成:重组融合蛋白是通过将病原体的蛋白抗原与创伤弧菌的鞭毛蛋白融合而制备的。鞭毛蛋白是序列号为1的创伤弧菌的FlaB。病原体的抗原是肺炎链球菌表面蛋白A(PsaA)的α-螺旋结构域和表面粘附因子A(PsaA)。流感病毒的HA(血凝素)亚单位和NA(神经氨酸酶)亚单位;或SARS病毒的刺突蛋白。用于粘膜施用的疫苗含有重组融合蛋白作为活性成分。

著录项

  • 公开/公告号KR101130884B1

    专利类型

  • 公开/公告日2012-04-12

    原文格式PDF

  • 申请/专利权人

    申请/专利号KR20090033083

  • 发明设计人 이준행;누엔충;이시은;김수영;

    申请日2009-04-16

  • 分类号C07K19/00;C07K14/28;A61K39/106;

  • 国家 KR

  • 入库时间 2022-08-21 17:08:19

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号